XBIT
Xbiotech·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XBIT
Xbiotech Inc.
A biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases
5217 Winnebago Ln, Austin, TX 78744
--
Xbiotech Inc., incorporated in Canada on March 22, 2005, is a clinical-stage biopharmaceutical company engaged in the discovery and cultivation of "true human" monoclonal antibodies for the treatment of a variety of diseases. Real human monoclonal antibodies are those that occur naturally in humans and are not modified from animal immunization methods.
Company Financials
EPS
XBIT has released its 2025 Q3 earnings. EPS was reported at -0.2, versus the expected 0, missing expectations. The chart below visualizes how XBIT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
